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A BS TR AC T
BACKGROUND
Riociguat, a member of a new class of compounds (soluble guanylate cyclase stim-
ulators), has been shown in previous clinical studies to be beneficial in the treat-
ment of chronic thromboembolic pulmonary hypertension.
METHODS
In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, 
we randomly assigned 261 patients with inoperable chronic thromboembolic pul-
monary hypertension or persistent or recurrent pulmonary hypertension after pul-
monary endarterectomy to receive placebo or riociguat. The primary end point was 
the change from baseline to the end of week 16 in the distance walked in 6 minutes. 
Secondary end points included changes from baseline in pulmonary vascular resis-
tance, N-terminal pro–brain natriuretic peptide (NT-proBNP) level, World Health 
Organization (WHO) functional class, time to clinical worsening, Borg dyspnea 
score, quality-of-life variables, and safety.
RESULTS
By week 16, the 6-minute walk distance had increased by a mean of 39 m in the 
riociguat group, as compared with a mean decrease of 6 m in the placebo group 
(least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P<0.001). 
Pulmonary vascular resistance decreased by 226 dyn · sec · cm–5 in the riociguat 
group and increased by 23 dyn · sec · cm–5 in the placebo group (least-squares mean 
difference, –246 dyn · sec · cm–5; 95% CI, –303 to –190; P<0.001). Riociguat was also 
associated with significant improvements in the NT-proBNP level (P<0.001) and 
WHO functional class (P = 0.003). The most common serious adverse events were 
right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the 
riociguat group and in 3% of the placebo group).
CONCLUSIONS
Riociguat significantly improved exercise capacity and pulmonary vascular re sistance 
in patients with chronic thromboembolic pulmonary hypertension. (Funded by Bayer 
HealthCare; CHEST-1 and CHEST-2 ClinicalTrials.gov numbers, NCT00855465 and 
NCT00910429, respectively.)
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Chronic thromboembolic pulmonary hypertension is characterized by obstruc-tion of the pulmonary vasculature by re-
sidual organized thrombi,1 leading to increased 
pulmonary vascular resistance, progressive pulmo-
nary hypertension, and right ventricular failure.2,3 
Patients with chronic thromboembolic pulmonary 
hypertension have a poor prognosis unless they 
receive treatment early.4
Pulmonary endarterectomy is the standard 
treatment for chronic thromboembolic pulmo-
nary hypertension and is the only potentially 
curative treatment.5 However, surgery is not an 
option for all patients; some patients are ineli-
gible for surgery owing to the occlusion of distal 
vessels or coexisting conditions, some decline 
surgery, and some do not have access to expert 
surgical centers.5-8 Operability should be assessed 
with the use of high-quality imaging, with each 
patient undergoing review at an experienced pul-
monary-endarterectomy center.6,7 Furthermore, 
some patients who undergo pulmonary endarter-
ectomy have persistent or recurrent pulmonary 
hypertension after surgery. To date, pharmaco-
logic therapies have been approved for pulmo-
nary arterial hypertension (group 1 in the Dana 
Point classification1) but not for chronic throm-
boembolic pulmonary hypertension (Dana Point 
group 4), highlighting a substantial unmet need.9
Riociguat is a member of a new class of ther-
apeutic agents called soluble guanylate cyclase 
stimulators.10 Impairment of nitric oxide synthe-
sis and signaling through the nitric oxide–soluble 
guanylate cyclase–cyclic guanosine monophos-
phate pathway is involved in the pathogenesis of 
pulmonary hypertension.11,12 Riociguat has a dual 
mode of action, directly stimulating soluble gua-
nylate cyclase independently of nitric oxide, and 
increasing the sensitivity of soluble guanylate 
cyclase to nitric oxide.10,11 Riociguat increases 
the level of cyclic guanosine monophosphate, 
resulting in vasorelaxation and antiproliferative 
and antifibrotic effects, as shown in experimen-
tal models of pulmonary hypertension.13,14
In previous clinical studies involving patients 
with pulmonary arterial hypertension or chronic 
thromboembolic pulmonary hypertension, rio-
ciguat significantly increased exercise capacity 
and improved hemodynamic variables.10,15 Here 
we present the results of the Chronic Thrombo-
embolic Pulmonary Hypertension Soluble Guanyl-
ate Cyclase–Stimulator Trial 1 (CHEST-1), a phase 3 
study investigating the efficacy and side-effect 
profile of riociguat in patients with chronic 
thromboembolic pulmonary hypertension who 
were considered by experienced surgeons to be 
ineligible for surgery or who had persistent or 
recurrent pulmonary hypertension after pulmo-
nary endarterectomy.
ME THODS
STUDY DESIGN AND OVERSIGHT
We conducted this 16-week, double-blind, ran-
domized, placebo-controlled study at 89 centers 
in 26 countries. The study was designed by the 
first author and the steering committee (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org) in collaboration 
with the sponsor, Bayer HealthCare. The institu-
tional review board at each participating center 
approved the protocol. Data were collected ac-
cording to Good Clinical Practice guidelines at 
the investigation sites. The steering committee 
had access to the complete database. The statisti-
cal analysis was performed by a statistician em-
ployed by the sponsor and was reviewed by the 
first author. The manuscript was prepared by the 
first author, and editorial assistance, funded by 
the sponsor, was provided by Adelphi Communi-
cations. The first author, with approval from the 
coauthors, made the decision to submit the man-
uscript for publication. The academic authors as-
sume full responsibility for the accuracy and 
completeness of the data and all the analyses, as 
well as for the fidelity of this report to the trial 
protocol, which is available at NEJM.org.
SELECTION OF PATIENTS
Patients 18 to 80 years of age were included if they 
had chronic thromboembolic pulmonary hyper-
tension that was adjudicated to be technically in-
operable or if they had persistent or recurrent pul-
monary hypertension after undergoing pulmonary 
endarterectomy. Additional inclusion criteria 
were a 6-minute walk distance of 150 to 450 m, 
pulmonary vascular resistance of more than 
300 dyn · sec · cm–5, and a mean pulmonary-artery 
pressure of at least 25 mm Hg. Chronic thrombo-
embolic pulmonary hypertension was diagnosed 
with the use of two or more of the following imag-
ing methods: ventilation–perfusion scanning, pul-
monary angiography, spiral computed tomogra-
phy, or magnetic resonance angiography.
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Patients were excluded if they had received an 
endothelin-receptor antagonist, prostacyclin ana-
logue, phosphodiesterase type 5 inhibitor, or nitric 
oxide donor within the 3 months before study 
entry. Written informed consent was obtained 
from all the patients.
STUDY PROCEDURES
Patients who were considered to be potentially 
eligible for trial participation after the initial 
screening were entered into a pretreatment phase 
to permit a systematic assessment of operability 
and a detailed evaluation of all other enrollment 
criteria. The criteria for inoperability and the 
specifics of their adjudication are provided in the 
Supplementary Appendix.
After the completion of the pretreatment phase, 
eligible patients were randomly assigned in a 1:2 
ratio to receive placebo or riociguat. The dose-
adjustment plan for riociguat is described in de-
tail in Figure S1 in the Supplementary Appendix. 
Briefly, riociguat was adjusted from a starting 
dose of 1 mg three times daily according to 
 systolic systemic arterial pressure and signs or 
symptoms of hypotension (final range, 0.5 mg 
to 2.5 mg three times daily). The doses reached 
at the end of the 8-week adjustment phase were 
considered to be the appropriate dose for the pa-
tient, and the patient continued taking the drug 
at that dose for another 8 weeks.
Patients were seen at weeks 2, 4, 6, and 8 
(during the dose-adjustment phase) and then at 
weeks 12 and 16 (during the maintenance phase). 
At each visit, clinical assessments and blood tests 
were performed. Patients who discontinued ther-
apy for any reason were withdrawn from the trial; 
these patients underwent an efficacy assessment 
at the termination visit and had no further effi-
cacy assessments after withdrawal. All surviving 
patients returned for a follow-up assessment of 
safety at 30 days. Patients completing the 16-week 
study were eligible to participate in a long-term, 
open-label extension study (CHEST-2).
OUTCOME MEASURES
The primary end point was the change from base-
line to the end of week 16 in the distance walked 
in 6 minutes. Secondary efficacy end points includ-
ed changes from baseline to the end of week 16 
in pulmonary vascular resistance, N-terminal 
pro–brain natriuretic peptide (NT-proBNP) level, 
World Health Organization (WHO) functional 
class (an adaptation of the New York Heart As-
sociation functional classification), time to clini-
cal worsening (as defined in the Supplementary 
Appendix), Borg dyspnea score (which ranges 
from 0 to 10, with 0 representing no dyspnea and 
10 maximal dyspnea), the score on the EuroQol 
Group 5-Dimension Self-Report Questionnaire 
(EQ-5D; in which scores range from –0.6 to 1.0, 
with higher scores indicating a better quality of 
life), and the score on the Living with Pulmonary 
Hypertension (LPH) questionnaire (an adapta-
tion of the Minnesota Living with Heart Failure 
Questionnaire, with scores ranging from 0 to 105 
and higher scores indicating a worse quality of 
life). Adverse events and laboratory variables were 
assessed throughout the study and during the 
safety follow-up period.
STATISTICAL ANALYSIS
For the study to detect a least-squares mean dif-
ference from baseline of 30 m in the 6-minute 
walk distance with riociguat, at a power of 90% 
and a two-sided significance level of 5%, we cal-
culated that we would need to enroll 174 patients 
in the riociguat group and 87 in the placebo 
group. The primary efficacy analysis was per-
formed with data from the modified intention-
to-treat population (all patients who underwent 
randomization and received at least one dose of 
the study medication). A per-protocol analysis 
was also performed (see the Supplementary Ap-
pendix). Missing values due to patient withdrawal 
or death were imputed as described in the Sup-
plementary Appendix.
For evaluation of the primary end point, a 
two-sided test at the 5% significance level for 
the difference in the treatment effect between 
the riociguat group and the placebo group was 
performed. The comparison was carried out with 
the use of analysis of covariance, with baseline 
value as a covariate and treatment group and 
region as main effects. This was followed by a 
test of normality of the residuals (Shapiro–Wilk 
test), and on rejection, a nonparametric strati-
fied Wilcoxon test was used to assess the change 
from baseline in the 6-minute walk distance.
The secondary efficacy variables were for-
mally tested if the primary comparison was 
significant at a two-sided level of 5%. A hierar-
chical testing procedure was performed, with 
the variables in the following order: pulmonary 
vascular resistance, NT-proBNP level, WHO func-
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tional class, time to clinical worsening, Borg 
dyspnea score, EQ-5D score, and LPH question-
naire score (see the Supplementary Appendix). 
The changes in the variables for the secondary 
efficacy end point that were measured on a semi-
continuous scale were analyzed with the use of 
the same methods as those for the 6-minute 
walk distance. Changes in WHO functional class 
and Borg dyspnea score were analyzed with the 
use of the stratified Wilcoxon test. Time to clini-
cal worsening was analyzed with the use of a 
stratified log-rank test, and safety was analyzed 
descriptively. Adverse events during the study 
period included all adverse events that started or 
worsened from the time of administration of the 
first dose of the study drug until 2 days after the 
administration of the last dose.
R ESULT S
PATIENTS
From February 2009 through February 2012, a 
total of 261 patients underwent randomization 
and received at least one dose of study medica-
tion (173 patients in the riociguat group and 88 
in the placebo group) (Fig. 1). The characteristics 
of the patients at baseline were well balanced be-
tween the two groups (Table 1). Most patients 
262 Underwent randomization
261 Received at least one dose
of study drug
446 Patients were screened
184 Were excluded
1 (<1%) Had adverse event
4 (1%) Died
164 (37%) Were not eligible
15 (3%) Withdrew consent
88 Were assigned to placebo 173 Were assigned to riociguat
13 (8%) Did not complete treatment
4 (2%) Had adverse event
2 (1%) Died
2 (1%) Had lack of efficacy
1 (1%) Did not adhere to treatment
2 (1%) Had protocol violation
2 (1%) Withdrew consent
83 (94%) Completed treatment 160 (92%) Completed treatment
1 (<1%) Underwent randomization
in error
5 (6%) Did not complete treatment
2 (2%) Had adverse event
2 (2%) Died
1 (1%) Had lack of efficacy
1 Died during
follow-up
Figure 1. Screening, Randomization, and Follow-up.
The one patient who underwent randomization in error was ineligible for the study; this patient was assigned to but 
not treated in the riociguat group. Of the five patients who did not complete treatment, one patient in the placebo 
group who withdrew owing to an adverse event died during the 30-day follow-up period.
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were in WHO functional class II or III, and more 
patients were classified as having inoperable 
chronic thromboembolic pulmonary hyperten-
sion (72% of all patients) than postoperative per-
sistent or recurrent pulmonary hypertension 
(28%). A total of 18 patients withdrew from the 
study before week 16 (Fig. 1).
DOSING
At week 16, a total of 77% of patients who were 
still participating in the study were taking the 
maximal riociguat dose of 2.5 mg three times 
daily, with 12%, 6%, 4%, and 1% taking riociguat 
at doses of 2.0 mg, 1.5 mg, 1.0 mg, and 0.5 mg 
three times daily, respectively. During the study, 
the dose of the study drug was decreased in 18 
patients (10%) in the riociguat group, as compared 
with 3 (3%) in the placebo group.
PRIMARY END POINT
At week 16, the 6-minute walk distance had in-
creased from baseline by a mean of 39 m in the 
riociguat group, as compared with a mean de-
crease of 6 m in the placebo group (least-squares 
mean difference, 46 m; 95% confidence interval 
[CI], 25 to 67; P<0.001), on the basis of an analy-
sis of the modified intention-to-treat population 
with missing values imputed (Table 2 and Fig. 2). 
In sensitivity analyses for missing data that used 
statistical methods for longitudinal data (see the 
Supplementary Appendix), the benefit of rio-
ciguat was similar to that observed in the main 
analysis (Table S1 in the Supplementary Appen-
dix). The increase in the 6-minute walk distance 
in the per-protocol population (Table S2 in the 
Supplementary Appendix) was consistent with 
the increase in the main analysis. The treatment 
Table 1. Baseline Demographic and Clinical Characteristics of the Patients.*
Characteristic
Placebo 
(N = 88)
Riociguat 
(N = 173)
Total 
(N = 261)
Female sex — no. (%) 54 (61) 118 (68) 172 (66)
Race — no. (%)†
White 65 (74) 120 (69) 185 (71)
Black 1 (1) 7 (4) 8 (3)
Asian 20 (23) 37 (21) 57 (22)
Not reported 2 (2) 8 (5) 10 (4)
Mixed 0 1 (1) 1 (<1)
Age — yr 59±13 59±14 59±14
Body-mass index‡ 28±5 27±6 27±6
Chronic thromboembolic pulmonary 
hypertension — no. (%)
Inoperable 68 (77) 121 (70) 189 (72)
Postoperative 20 (23) 52 (30) 72 (28)
WHO functional class — no. (%)§
I 0 3 (2) 3 (1)
II 25 (28) 55 (32) 80 (31)
III 60 (68) 107 (62) 167 (64)
IV 2 (2) 8 (5) 10 (4)
Data missing 1 (1) 0 1 (<1)
6-Min walk distance — m 356±75 342±82 347±80
* Plus–minus values are means ±SD. There were no significant differences in baseline characteristics between the riociguat 
and placebo groups. 
† Race was determined by the investigator.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The World Health Organization (WHO) functional class ranges from I to IV, with higher numbers indicating greater 
functional limitations.
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effect was consistent across predefined patient 
subgroups (Fig. S2 and Table S3 in the Supple-
mentary Appendix).
SECONDARY END POINTS
Pulmonary vascular resistance decreased by 
226 dyn · sec · cm–5 in the riociguat group, as com-
pared with an increase of 23 dyn · sec · cm–5 in the 
placebo group (least-squares mean difference, 
–246 dyn · sec · cm–5; 95% CI, –303 to –190; P<0.001) 
(Table 2). Riociguat was also associated with sig-
nificant improvement in other hemodynamic vari-
ables, including mean pulmonary-artery pressure 
and cardiac output (Table 2). Levels of NT-proBNP 
were significantly reduced in patients treated 
with riociguat, and changes in WHO functional 
class at 16 weeks also significantly favored rio-
ciguat (Table 2).
There was no significant difference in the in-
cidence of clinical-worsening events between the 
riociguat and placebo groups (2% and 6%, re-
spectively; P = 0.17) (Table 3). The Kaplan–Meier 
estimates of the proportion of patients with 
clinical worsening are provided in Figure S3 in 
the Supplementary Appendix.
On the basis of the prespecified hierarchical 
testing procedure, analyses of the Borg dyspnea 
score and quality-of-life data were considered 
exploratory (Table S4 in the Supplementary Ap-
pendix). The Borg dyspnea score decreased by 
0.8 points in the riociguat group and increased 
by 0.2 points in the placebo group (P = 0.004). 
There was a nominally significant difference 
between the two groups in the change in the 
EQ-5D score but not in the change in the LPH 
questionnaire score (Table 2).
SAFETY
The adverse events that occurred most frequently 
during the study period are shown in Table 3. 
The most frequently occurring serious adverse 
events were right ventricular failure (in 3% of pa-
tients in each group), syncope (in 2% of the rio-
ciguat group and 3% of the placebo group), and 
hemoptysis (in 2% of the riociguat group). Drug-
related serious adverse events in the riociguat group 
included syncope in three patients (2%) and gas-
tritis, acute renal failure, and hypotension in one 
patient each (1%); in the placebo group, syncope 
and trauma occurred in one patient each (1%).
Five patients (3%) in the riociguat group and 
two (2%) in the placebo group discontinued the H
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study drug owing to adverse events. For one pa-
tient in the riociguat group, the adverse events 
(diarrhea, heartburn, nausea, vomiting, and head-
ache) leading to discontinuation were considered 
by the investigator to be related to the study 
drug. Four patients (2%) in the riociguat group 
and two (2%) in the placebo group discontinued 
the study drug owing to serious adverse events. 
In the riociguat group, these events included right 
heart decompensation, vaginal bleeding, overdose 
of study drug (attempted suicide), and worsening 
of general condition; in the placebo group, the 
events included right heart failure and cardiocir-
culatory arrest. None of these serious adverse 
events were considered to be related to the study 
drug. Deaths related to adverse events occurred 
in two patients (1%) in the riociguat group (one 
each with heart failure and acute renal failure) 
and in three patients (3%) in the placebo group 
(one each with respiratory insufficiency, circula-
tory arrest, and cardiac arrest). The case of acute 
renal failure was considered by the investigator 
to be related to the study drug.
LONG-TERM EXTENSION STUDY
A total of 237 patients (98% of the patients who 
completed the study) entered the long-term ex-
tension study, CHEST-2, in which study assign-
ments were concealed for the first 8 weeks and 
treatment was open-label thereafter. Of these pa-
tients, 194 (129 patients from the riociguat group 
and 65 from the placebo group in CHEST-1) were 
included in an interim analysis in CHEST-2 that 
included data collected up to May 2012, and 182 
(94%) were still participating in the study after a 
median treatment duration of 336 days. An explor-
atory analysis of the first 12 weeks of CHEST-2 
showed further increases in the 6-minute walk 
distance in the group that received riociguat in 
CHEST-1. A mean (±SD) increase of 63±64 m over 
the baseline distance in CHEST-1 for the 129 pa-
tients in this group was observed at week 12 of 
CHEST-2. The same group had an increase of 
51±62 m at week 16 of CHEST-1.
DISCUSSION
In this trial, riociguat, a soluble guanylate cyclase 
stimulator, significantly improved exercise ca-
pacity in patients with chronic thromboembolic 
pulmonary hypertension who were deemed to be 
ineligible for surgery or who had persistent or 
recurrent pulmonary hypertension after undergo-
ing pulmonary endarterectomy. Significant im-
provements were also observed in the clinically 
relevant secondary end points, including pulmo-
nary vascular resistance, NT-proBNP level, and 
WHO functional class.
Pulmonary endarterectomy, the only treat-
ment option currently recommended for patients 
with chronic thromboembolic pulmonary hyper-
tension, improves hemodynamics, exercise ca-
pacity, and survival.16-18 These patients should 
always be assessed for operability at an experi-
enced center.6,9 However, only approximately 
63% of patients are eligible for surgery,5 and the 
disorder persists or recurs after surgery in 5 to 
35% of patients.16,19-21
Hemodynamic measurements, an important 
end point in studies of pulmonary hypertension, 
provide a robust and objective measure of the status 
of the pulmonary circulation and are predictive of 
the outcome. For example, when baseline pulmo-
nary vascular resistance exceeds 900 dyn · sec · cm–5, 
mortality has been shown to increase.22 Reductions 
in pulmonary vascular resistance have been asso-
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Figure 2. Mean Change from Baseline in the 6-Minute Walk Distance.
Mean (±SE) changes from baseline in the distance walked in 6 minutes during 
the 16-week study are shown in the modified intention-to-treat population 
without imputation of missing values, with the imputed values also pro-
vided at week 16. The number at each data point indicates the number of 
patients included in the assessment at that time point. The least-squares 
mean difference in the distances at week 16 was 46 m (95% CI, 25 to 67; 
P<0.001). The last observed value (not including follow-up) was carried for-
ward for patients who completed the study or withdrew; the worst value 
(0 m) was imputed in the case of death or clinical worsening without a 
 termination visit or without a measurement at the termination visit.
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ciated with improved outcomes of medical treat-
ment for pulmonary arterial hypertension23,24 and 
increased survival after surgery among patients 
with chronic thromboembolic pulmonary hyper-
tension.25
The magnitude of the decrease in pulmonary 
vascular resistance with riociguat that we ob-
served in this study appears to be clinically rele-
vant, on the basis of the results of previous stud-
ies of therapies for pulmonary hypertension.26,27 
It has also been shown that high preoperative 
levels of pulmonary vascular resistance increase 
the risk of death during surgery among patients 
with chronic thromboembolic pulmonary hyper-
tension,25 and a reduction in pulmonary vascular 
resistance before surgery may improve the post-
operative course.28 Future studies with riociguat 
could address its usefulness in reducing preop-
erative hemodynamics and improving physical 
condition in patients who are eligible for pulmo-
nary endarterectomy.15
The current study also showed a benefit of 
riociguat with respect to WHO functional class. 
In addition to its direct relevance to patients’ 
perception of a treatment benefit, improvement 
in functional class correlates with survival among 
patients with chronic thromboembolic pulmo-
nary hypertension and those with pulmonary 
arterial hypertension.24,29,30
The only other drug that has been evaluated 
for chronic thromboembolic pulmonary hyper-
tension in a randomized, controlled study is the 
endothelin-receptor antagonist bosentan. In the 
16-week Bosentan Effects in Inoperable Forms 
of Chronic Thromboembolic Pulmonary Hyper-
tension (BENEFIT) study, bosentan significantly 
decreased pulmonary vascular resistance, as com-
pared with placebo (treatment effect, –24.1%), 
but not the 6-minute walk distance (mean differ-
ence, 2.2 m).26 Although direct comparisons of 
the results of different clinical trials require cau-
tion, in the current study, riociguat significantly 
improved both hemodynamics and exercise ca-
pacity, as compared with placebo, and the mag-
nitude of the change in pulmonary vascular re-
sistance was greater than that observed with 
bosentan. Moreover, riociguat was associated 
with robust improvement in the 6-minute walk 
distance both in patients who were ineligible for 
surgery and in those with persistent or recurrent 
pulmonary hypertension after pulmonary endarter-
ectomy (increases of 54 m and 26 m, respectively). 
Table 3. Clinical Worsening and Adverse Events.*
Event Placebo  (N = 88)
Riociguat  
(N = 173)
number of patients (percent)
Clinical worsening
All events 5 (6) 4 (2)†
Hospitalization due to pulmonary 
 hypertension
1 (1) 0
Start of new treatment for pulmonary 
hypertension
1 (1) 2 (1)
Decrease in 6-min walk distance due 
to pulmonary hypertension
2 (2) 1 (1)
Persistent worsening of WHO func-
tional class due to pulmonary 
 hypertension
1 (1) 0
Death 3 (3) 2 (1)
Adverse events
Any 76 (86) 159 (92)
Headache 12 (14) 43 (25)
Dizziness 11 (12) 39 (23)
Dyspepsia 7 (8) 31 (18)
Peripheral edema 18 (20) 27 (16)
Nasopharyngitis 8 (9) 26 (15)
Nausea 7 (8) 19 (11)
Vomiting 3 (3) 17 (10)
Diarrhea 4 (5) 17 (10)
Hypotension 3 (3) 16 (9)‡
Upper respiratory tract infection 4 (5) 10 (6)
Increase in international normalized 
ratio
4 (5) 10 (6)
Constipation 1 (1) 10 (6)
Prolonged activated partial-thrombo-
plastin time
2 (2) 8 (5)
Cough 16 (18) 9 (5)
Chest pain 4 (5) 7 (4)
Dyspnea 12 (14) 8 (5)
Back pain 5 (6) 7 (4)
Increase in serum creatinine level 5 (6) 3 (2)
Pain in extremity 5 (6) 3 (2)
Insomnia 6 (7) 4 (2)
Syncope 3 (3) 4 (2)
* The adverse events listed are those that occurred in at least 5% of the patients 
in either group during the treatment period or up to 2 days after the end of 
treatment. The incidence of syncope as an adverse event of special interest is 
also reported.
† P = 0.17 as compared with placebo, with the use of a stratified log-rank test.
‡ Of the 16 cases of hypotension reported in the riociguat group, 8 were reported 
as mild and 8 as moderate.
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This may suggest that the nitric oxide–soluble gua-
nylate cyclase–cyclic guanosine monophosphate 
pathway has a role in the pathologic features 
underlying chronic thromboembolic pulmonary 
hypertension, including impairments in nitric 
oxide–mediated production of endogenous cyclic 
guanosine monophosphate and in progressive 
remodeling of the remaining perfused areas of 
the pulmonary vascular bed.2,31
An obvious limitation of CHEST-1 was the lack 
of follow-up efficacy measurements in patients 
who withdrew from the study. However, sensitiv-
ity analyses that used a variety of approaches to 
impute missing data suggest that the results are 
reliable, despite these losses to follow-up.
In conclusion, riociguat significantly im-
proved the 6-minute walk distance, pulmonary 
vascular resistance, and other clinical outcomes 
in patients with chronic thromboembolic pul-
monary hypertension who were deemed to be 
ineligible for surgery or who had persistent or 
recurrent pulmonary hypertension after under-
going pulmonary endarterectomy.
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